Synthetic
peptide vaccines targeting
B-cell epitopes of the extracellular domain of the HER-2
oncoprotein were evaluated for their capacity to elicit HER-2-specific
antibodies with antiproliferative activity. Several HER-2
B-cell epitopes were identified by computer-aided analysis of
protein antigenicity, and selected
B-cell epitopes were synthesized colinearly with a promiscuous T-helper
epitope (208-302) derived from the measles virus fusion
protein at either the NH2 or COOH terminus linked via a four-residue turn sequence (GPSL). In addition, one
epitope sequence, 628-647, was mutated to optimize
disulfide pairing to mimic the native HER-2 receptor. All of the four selected
epitopes elicited high-titered
antibodies in outbred rabbits with exceptionally high titers for MVF-HER-2(628-647). These
antibodies were cross-reactive with the native HER-2 receptor.
Antibodies elicited by MVF HER-2(628-647) inhibited proliferation of human HER-2-overexpressing
breast cancer cells in vitro and caused their antibody-dependent cell-mediated cytotoxicity. Furthermore, immunization with MVF-HER-2(628-647) prevented the spontaneous development of HER-2/neu-overexpressing mammary
tumors in 83% of transgenic mice. The engineered, chimeric
peptide B-cell immunogen MVF-HER-2(628-647) may have applications in the prevention of HER-2-overexpressing
cancers.